ClinicalTrials.gg
CompletedNCT03882970SURPASS-3Updated Jan 19, 2022Results posted

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

A Phase 3 interventional study of Tirzepatide and Insulin Degludec in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 122 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
4th of 43
1,444 · median 160
Started
2019
with 7 others
Phase 3
17 of 43
1 open now
Registered
8th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must:

    • Have been diagnosed with type 2 diabetes mellitus (T2DM)
    • Have between ≥7.0% and ≤10.5%
    • Be on stable treatment with unchanged dose of metformin or metformin plus an SGLT-2 inhibitor for at least 3 months before screening
    • Be of stable weight (± 5%) for at least 3 months before screening
    • Have a ≥25 kilograms per meter squared (kg/m2) at screening

Exclusion criteria

Exclusion Criteria:

  • Participants must not:

    • Have type 1 diabetes mellitus
    • Have had chronic or acute pancreatitis any time prior to study entry
    • Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment
    • Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
    • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood (ALT) enzyme level >3.0 times the (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if their ALT level is ≤3.0 the ULN for the reference range
    • Have an estimated \<45 mL/minute/1.73 m2 (or lower than the country specific threshold for using the protocol required dose of metformin per local label)
    • Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
    • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
    • Have been taking any other diabetes medicines other than metformin, or metformin plus an SGLT-2 inhibitor during the last 3 months
    • Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,444 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    10 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Active comparator
    Insulin Degludec

    Insulin degludec administered SC once a day.

    Drug: Insulin Degludec

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline in HbA1c (5 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  2. Change From Baseline in Body Weight

    LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

    Time frame: Baseline, Week 52

  3. Change From Baseline in Fasting Serum Glucose

    LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  4. Percentage of Participants Achieving an HbA1c Target Value of <7%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline Value, Pooled Country, Baseline OAM Use (Met, Met plus SGLT-2i), Treatment, Visit and Visit\*Treatment.

    Time frame: Week 52

  5. Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. LS mean was determined by mixed-model repeated measures (MMRM) model with variables Baseline + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  6. Percentage of Participants Who Achieved Weight Loss ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5%

    Time frame: Week 52

  7. Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score

    DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 52 or early termination.The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline DTSQs + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment (Type III sum of squares).

    Time frame: Week 52

  8. Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia

    The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL (\<3.0 mmol/L) or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: Number of episodes = Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.

    Time frame: Baseline through Safety Follow-Up (Up to Week 56)

07

Results

Posted Jan 19, 2022

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Started359361359365
Received at least one dose of study drug358360359360
Completed333321340331
Not completed26401934
Withdrew: Adverse event5731
Withdrew: Death1211
Withdrew: Lost to follow-up8955
Withdrew: Physician decision0222
Withdrew: Protocol violation2000
Withdrew: Withdrawal by subject817722
Withdrew: Personal reason2313

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Percentage of HbA1c10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)-2.20 ± 0.051-2.37 ± 0.050-1.34 ± 0.049
Statistical analysis
  • 10 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.86 · 95% CI -1.00 to -0.72
  • 15 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.04 · 95% CI -1.17 to -0.90
SecondaryChange From Baseline in HbA1c (5 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c (5 mg)
Percentage of HbA1c5 mg TirzepatideInsulin Degludec
Change From Baseline in HbA1c (5 mg)-1.93 ± 0.050-1.34 ± 0.049
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.59 · 95% CI -0.73 to -0.45
SecondaryChange From Baseline in Body Weight

LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Change From Baseline in Body Weight-7.5 ± 0.37-10.7 ± 0.37-12.9 ± 0.372.3 ± 0.37
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -9.8 · 95% CI -10.8 to -8.8
  • 10 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.0 · 95% CI -14.0 to -11.9
  • 15 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = <0.001 · Ls mean difference: -15.2 · 95% CI -16.2 to -14.2
SecondaryChange From Baseline in Fasting Serum Glucose

LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram per Deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligram per Deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Change From Baseline in Fasting Serum Glucose-48.2 ± 1.82-54.8 ± 1.86-59.2 ± 1.85-55.7 ± 1.81
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = 0.004 · Ls mean difference: 7.5 · 95% CI 2.4 to 12.5
  • 10 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = 0.751 · Ls mean difference: 0.8 · 95% CI -4.3 to 5.9
  • 15 mg Tirzepatide vs Insulin Degludec · Mixed Models Analysis · p = 0.168 · Ls mean difference: -3.6 · 95% CI -8.7 to 1.5
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <7%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline Value, Pooled Country, Baseline OAM Use (Met, Met plus SGLT-2i), Treatment, Visit and Visit\*Treatment.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an HbA1c Target Value of <7%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Percentage of Participants Achieving an HbA1c Target Value of <7%82.4489.7192.6361.25
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.45 · 95% CI 2.38 to 5.01
  • 10 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.02 · 95% CI 4.55 to 10.84
  • 15 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.79 · 95% CI 6.65 to 17.48
SecondaryMean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. LS mean was determined by mixed-model repeated measures (MMRM) model with variables Baseline + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mg/dL
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
mg/dL5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values-52.6 ± 1.20-59.7 ± 1.22-60.6 ± 1.20-48.0 ± 1.18
SecondaryPercentage of Participants Who Achieved Weight Loss ≥5%

Percentage of Participants who Achieved Weight Loss ≥5%

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss ≥5%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Percentage of Participants Who Achieved Weight Loss ≥5%66.0183.7187.826.27
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 29.78 · 95% CI 18.35 to 48.35
  • 10 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 79.88 · 95% CI 47.56 to 134.17
  • 15 mg Tirzepatide vs Insulin Degludec · Regression, Logistic · p = <0.001 · Odds ratio (or): 110.77 · 95% CI 64.73 to 189.55
SecondaryDiabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score

DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 52 or early termination.The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline DTSQs + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SGLT-2i) + Treatment (Type III sum of squares).

Time frame:
Week 52
Reported as:
Least squares mean · units on a scale
Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score
units on a scale5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Hyperglycemia-1.4 ± 0.11-1.4 ± 0.11-1.6 ± 0.11-1.1 ± 0.11
Hypoglycemia-1.1 ± 0.12-0.9 ± 0.12-1.0 ± 0.12-0.7 ± 0.12
Treatment Satisfaction Score15.6 ± 0.2715.5 ± 0.2815.6 ± 0.2812.6 ± 0.27
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.096 · Ls mean difference: -0.26 · 95% CI -0.57 to 0.05
  • 10 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.113 · Ls mean difference: -0.25 · 95% CI -0.57 to 0.06
  • 15 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.003 · Ls mean difference: -0.47 · 95% CI -0.78 to -0.16
  • 5 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.014 · Ls mean difference: -0.41 · 95% CI -0.74 to -0.08
  • 10 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.280 · Ls mean difference: -0.18 · 95% CI -0.51 to 0.15
  • 15 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = 0.129 · Ls mean difference: -0.26 · 95% CI -0.59 to 0.07
  • 5 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = <0.001 · Ls mean difference: 3.01 · 95% CI 2.26 to 3.75
  • 10 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = <0.001 · Ls mean difference: 2.90 · 95% CI 2.15 to 3.65
  • 15 mg Tirzepatide vs Insulin Degludec · ANCOVA · p = <0.001 · Ls mean difference: 2.99 · 95% CI 2.24 to 3.74
SecondaryRate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia

The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL (\<3.0 mmol/L) or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: Number of episodes = Pooled Country + Baseline OAM Use (Met, Met plus SGLT-2i) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.

Time frame:
Baseline through Safety Follow-Up (Up to Week 56)
Reported as:
Mean · Episodes/participant/365.25 days
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia
Episodes/participant/365.25 days5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia0.0137 ± 0.00560.0108 ± 0.00440.0275 ± 0.01430.1020 ± 0.0568

Adverse events

Collected over Baseline Up To 56 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide1/358 (0.3%)29/358 (8.1%)124/358 (34.6%)
10 mg Tirzepatide2/360 (0.6%)20/360 (5.6%)157/360 (43.6%)
15 mg Tirzepatide1/359 (0.3%)26/359 (7.2%)179/359 (49.9%)
Insulin Degludec1/360 (0.3%)22/360 (6.1%)66/360 (18.3%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
Maternal exposure during pregnancyInjury, poisoning and procedural complications0/1581/1650/1650/147
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1581/1650/1650/147
Cervical dysplasiaReproductive system and breast disorders0/1580/1651/1650/147
Acute myocardial infarctionCardiac disorders2/3580/3600/3592/360
Non-cardiac chest painGeneral disorders2/3580/3600/3590/360
Transient ischaemic attackNervous system disorders2/3580/3600/3590/360
PneumoniaInfections and infestations0/3580/3602/3592/360
Testicular neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2000/1950/1940/213
Atrial fibrillationCardiac disorders1/3580/3600/3590/360
Atrial tachycardiaCardiac disorders1/3580/3600/3590/360
Most frequent other events
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Degludec
NauseaGastrointestinal disorders41/35881/36085/3596/360
DiarrhoeaGastrointestinal disorders55/35859/36056/35914/360
Decreased appetiteMetabolism and nutrition disorders22/35837/36043/3592/360
VomitingGastrointestinal disorders21/35834/36036/3594/360
DyspepsiaGastrointestinal disorders14/35832/36018/3590/360
Abdominal painGastrointestinal disorders7/35817/36023/3594/360
NasopharyngitisInfections and infestations11/35814/36015/35922/360
Lipase increasedInvestigations21/35816/36020/3597/360
HypertensionVascular disorders11/3587/36011/35921/360

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
Mean57.20 ± 10.1357.40 ± 9.6657.50 ± 10.2457.50 ± 10.0857.40 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
Female158165165148636
Male201196194217808
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
Hispanic or Latino10910896108421
Not Hispanic or Latino2472532592561015
Unknown or Not Reported30418
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
American Indian or Alaska Native01124
Asian2019201978
Native Hawaiian or Other Pacific Islander10214
Black or African American131281144
White3243293273321312
More than one race10102
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
Argentina57545657224
Austria784827
Greece33353534137
Hungary36373737147
Italy688830
Poland33333333132
Puerto Rico8711935
Romania54545353214
South Korea9108936
Spain2121222286
Taiwan9810936
Ukraine1111121145
United States75757075295
Hemoglobin A1c
Hemoglobin A1c(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin DegludecTotal
Mean8.17 ± 0.898.18 ± 0.898.21 ± 0.948.12 ± 0.948.17 ± 0.91
08

Study locations

122 sites
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Valley Research
    Fresno, California 93720, United States
  • National Research Institute
    Huntington Park, California 90255, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • East Coast Clinical Research
    Jacksonville, Florida 32204, United States
  • East Coast Institute For Research
    Jacksonville, Florida 32216, United States
  • Bayside Clinical Research, LLC
    New Port Richey, Florida 34655, United States
  • East Coast Institute For Research
    Macon, Georgia 31210, United States
  • Sky Clinical Research Network
    Union City, Georgia 30291, United States
  • Elite Clinical Trials LLLP
    Blackfoot, Idaho 83221, United States
  • Humphreys Diabetes Center
    Boise, Idaho 83702, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Springfield Diabetes & Endocrine Center
    Springfield, Illinois 62711, United States
  • Crescent City Clinical Research
    Metairie, Louisiana 70006, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • Troy Internal Medicine, PC
    Troy, Michigan 48098, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Palm Research Center
    Las Vegas, Nevada 89128, United States
  • Palm Research Center
    Las Vegas, Nevada 89148, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • The Corvallis Clinic P.C.
    Corvallis, Oregon 97330, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Detweiler Family Medicine
    Lansdale, Pennsylvania 19446, United States
  • Office of Dr. Osvaldo Brusco
    Corpus Christi, Texas 78414, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
  • Mautalen Salud e Investigación - Servicio de Endocrinología
    Caba, Buenos Aires C1128AAF, Argentina
  • Investigaciones Medicas IMOBA S.R.L.
    Caba, Buenos Aires C1179AAB, Argentina
  • CEDIC-Centro de Investigaciones Clinicas
    Caba, Buenos Aires C1425DES, Argentina
  • Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
    Ciudad Autonoma de, Buenos Aires C1119ACN, Argentina
  • CIPADI
    Godoy Cruz, Mendoza M5501ARP, Argentina
  • AXISMED SRL - Bioclinica Research Network
    Buenos Aires, C1430CKE, Argentina
  • Centro Médico Viamonte
    Ciudad Autonoma de Buenos Aire, C1120AAC, Argentina
  • Instituto Centenario
    Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
  • CENUDIAB
    Ciudad Autonoma de Buenos Aire, C1440AAD, Argentina
  • Landesklinikum Korneuburg-Stockerau, Standort Stockerau
    Stockerau, Niederösterreich 2000, Austria
  • Universitätsklinikum Graz
    Graz, Steiermark 8036, Austria
  • Universitätsklinikum Salzburg
    Salzburg, 5020, Austria
  • KA Rudolfstiftung
    Wien, 1030, Austria
  • Iatriko Palaiou Falirou, Medical Center
    Palaio Faliro, Athens 17562, Greece
  • Laiko General Hospital of Athens
    Ampelokipoi, Attica 11527, Greece
  • Gen Hospital of Athens G Gennimatas
    Athens, Attiki 11527, Greece
  • General Hospital of Thessaloniki Papageorgiou
    N. Efkarpia, Thessaloniki 56403, Greece
  • Thermi Clinic
    Thermi, Thessaloniki 57001, Greece
  • Athens Euroclinic
    Athens, 11521, Greece
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • AHEPA Hospital
    Thessaloniki, 54636, Greece
  • Ippokrateio General Hospital of Thessaloniki
    Thessaloniki, 54639, Greece
  • Euromedica - General Clinic of Thessaloniki
    Thessaloniki, 54645, Greece
  • Kenezy Gyula Korhaz es Rendelointezet
    Debrecen, Hajdu-Bihar 4031, Hungary
  • Szent Margit Rendelointezet
    Budapest, 1032, Hungary
  • ClinDiab Kft.
    Budapest, 1089, Hungary
  • XIII.ker Onkormanyzat Egeszsegugyi Szolgalat
    Budapest, 1139, Hungary
  • Strazsahegy Medicina Bt.
    Budapest, 1171, Hungary
  • TRANTOR 99 Bt.
    Budapest, 1213, Hungary
  • Kanizsai Dorottya Korhaz
    Nagykanizsa, 8800, Hungary
  • Zala Megyei Szent Rafael Korhaz
    Zalaegerszeg, 8900, Hungary
  • Azienda ospedaliero-universitaria Mater Domini
    Germaneto, Catanzaro 88100, Italy
  • Policlinico Univ. Agostino Gemelli
    Roma, Lazio 00168, Italy
  • Centro Cardiologico Monzino, IRCCS
    Milano, MI 20138, Italy
  • Azienda Ospedaliera Policlinico Consorziale
    Bari, 70124, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24128, Italy
  • Ospedale Santa Maria Goretti
    Latina, 04100, Italy
  • Bucheon St. Mary's Hospital
    Bucheon,, Gyeonggi-do 14647, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Hanyang University Guri Hospital
    Guri-si, Gyeonggido 11923, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, Korea 06591, Korea, Republic of
  • Korea University Ansan Hospital
    Ansan-si, 15355, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Kyunghee University Hospital at Gangdong
    Seoul, 05278, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Ambulatorium Barbara Bazela
    Elblag, Warminsko-Mazurki 82300, Poland
  • NZOZ ZDROWIE Osteo-Medic
    Bialystok, 15-351, Poland
  • Poradnia Diabetologiczna SN ZOZ Lege Artis
    Bialystok, 15-404, Poland
  • NZOZ Diab-Endo-Met
    Krakow, 31-261, Poland
  • Gabinet Lekarski Malgorzata Saryusz-Wolska
    Lodz, 90-132, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
    Lodz, 90-242, Poland
  • NZOZ Przychodnia Specjalistyczna MEDICA
    Lublin, 20-538, Poland
  • NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek
    Ruda Slaska, 41-709, Poland
  • Latin Clinical Trial Center
    San Juan, 00909, Puerto Rico
  • GCM Medical Group PSC
    San Juan, 00917, Puerto Rico
  • San Miguel Medical
    Trujillo Alto, 00976, Puerto Rico
  • S. C. Grandmed S.R.L., Str.
    Oradea, Bihor 410159, Romania
  • Spitalul Judetean de Urgenta Satu Mare
    Satu-Mare, Jud Satu-Mare 440055, Romania
  • SC Diamed Obesity SRL
    Galati, Judetul Galati 800291, Romania
  • CMI DNBM Dr. Pop Lavinia
    Baia Mare, Maramures 430222, Romania
  • Cosamext SRL
    Targu Mures, Mures 540098, Romania
  • Societatea Civila Medicala "Dr. Paveliu"
    Bucuresti, Sect.5 050538, Romania
  • Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL
    Brasov, 500283, Romania
  • Cabinetul Medical Nicodiab SRL
    Bucharest, 010507, Romania
  • SC Nutrilife SRL
    Bucuresti, 013671, Romania

Showing the first 100 of 122 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5. Epub 2022 Apr 22. PubMed 35468325 ↗
  • Battelino T, Bergenstal RM, Rodriguez A, Fernandez Lando L, Bray R, Tong Z, Brown K. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022 Jun;10(6):407-417. doi: 10.1016/S2213-8587(22)00077-8. Epub 2022 Apr 22. Erratum In: Lancet Diabetes Endocrinol. 2022 Aug;10(8):e8. doi: 10.1016/S2213-8587(22)00169-3. PubMed 35468321 ↗
  • Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24. PubMed 35210595 ↗
  • Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, Bray R, Rodriguez A. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. PubMed 34370970 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2020, 20 months.

Results were first posted in Jan 2022, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 20, 2019
StartActual
Apr 1, 2019
Primary completionActual
Dec 11, 2020
CompletionActual
Jan 4, 2021
Results first posted
Jan 19, 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03882970
Responsible party
Sponsor
First posted
Mar 20, 2019
Start date
Apr 1, 2019
Primary completion
Dec 11, 2020
Completion
Jan 4, 2021
Results posted
Jan 19, 2022
Last update
Jan 19, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion